News
AVEO
--
0.00%
--
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation By The U.S. FDA For The Treatment Of Relapsed Or Recurrent Head And Neck Squamous Cell Carcinoma
AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for
Benzinga · 6d ago
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
BOSTON, September 20, 2021--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the trea...
Business Wire · 6d ago
Great news for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Insiders acquired stock in large numbers last year
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Simply Wall St. · 09/13 10:46
A Trio of Stocks Growing Capex Fast
GuruFocus News · 09/09 15:53
Aveo Pharmaceuticals Inc (AVEO) President & CEO Michael P Bailey Bought $97,200 of Shares
GuruFocus News · 09/03 04:08
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
BOSTON, August 30, 2021--AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences:
Business Wire · 08/30 11:00
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/05 22:45
Recap: AVEO Pharmaceuticals Q2 Earnings
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.76% year over year to ($0.40), which beat the estimate of ($0.45).
Benzinga · 08/05 21:42
AVEO Pharmaceuticals EPS beats by $0.10, beats on revenue
AVEO Pharmaceuticals (NASDAQ:AVEO): Q2 GAAP EPS of -$0.40 beats by $0.10. Revenue of $7.6M (+913.3% Y/Y) beats by $0.64M. AVEO believes its $102.9M in cash, cash equivalents and marketable securities
Seekingalpha · 08/05 21:25
BRIEF-Aveo Pharmaceuticals Q2 Loss Per Share $0.40
reuters.com · 08/05 21:14
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
--- Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO(R) (nivolumab) on Track to Initiate Enrollment in 3Q 2021 -
Business Wire · 08/05 20:05
-- Earnings Flash (AVEO) AVEO ONCOLOGY Reports Q2 Revenue $7.6M, vs. Street Est of $6.96M
MT Newswires · 08/05 16:24
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 08/01 14:13
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO's management team will host a conference call ...
Business Wire · 07/29 11:00
HC Wainwright & Co. Maintains Buy on AVEO Pharmaceuticals, Lowers Price Target to $19
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains AVEO Pharmaceuticals (NASDAQ:AVEO) with a Buy and lowers the price target from $27 to $19.
Benzinga · 07/12 10:06
--HC Wainwright Adjusts Price Target on AVEO Pharmaceuticals to $19 From $27, Keeps Buy Rating
MT Newswires · 07/12 07:31
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
Benzinga · 07/11 20:45
AVEO Oncology To Hose Key Opinion Leader Webinar On FOTIVDA For Relapsed Or Refractory Renal Cell Carcinoma On July 16
AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib),
Benzinga · 07/08 20:06
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA(R) (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
--FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch
Business Wire · 07/08 20:05
Webull provides a variety of real-time AVEO stock news. You can receive the latest news about Aveo through multiple platforms. This information may help you make smarter investment decisions.
About AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).